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ABSTRACT
Background Severe aortic stenosis (AS) is one of the 
most common and most serious valve diseases. Without 
timely intervention with surgical aortic valve replacement 
or transcatheter aortic valve replacement, patients have 
an estimated survival of 2–3 years. Guidelines for the 
treatment of AS have been developed, but studies suggest 
that as many as 42% of patients with AS are not treated 
according to these recommendations.
The aims of this registry are to delineate the caseload 
of patients with AS, outline the management of these 
patients and determine appropriateness of treatments in 
participating centres with and without onsite access to 
surgery and percutaneous treatments.
Methods/design The IMPULSE enhanced registry is 
an international, multicentre, prospective, observational 
cohort registry conducted at four central full access 
centres (tertiary care hospitals) and at least two satellite 
centres per hub (primary/secondary care hospitals). An 
estimated 800 patients will be enrolled in the registry and 
patient follow-up will last for 12 months.
Discussion In addition to the primary aims determining 
the caseload management and outcome of patients with 
AS in primary, secondary and tertiary care settings, the 
registry will also determine a time course for the transition 
from asymptomatic to symptomatic status and the 
diagnostic steps, treatment decisions and the identification 
of decision-makers in tertiary versus primary/secondary 
care hospitals. The last patient will be enrolled in the 
registry in 2018 and results of the registry are anticipated 
in 2019.
Registration number NCT03112629.
BaCkgRounD
Aortic stenosis (AS) is one of the most 
common and most serious valve diseases. 
The prevalence of AS increases with age, 
affecting approximately 0.2%, 1.3%, 3.9% 
and 9.8% of patients aged 50–59 years, 
60–69 years, 70–79 years and 80–89 years, 
respectively.1 In Europe, it is estimated that 
there are approximately 4.9 million patients 
Key questions
What is already known about this subject?
 ► Severe aortic stenosis (AS) is one of the most com-
mon and most serious valve diseases. With the 
onset of AS related symptoms, patients have an 
estimated survival of 2–3 years without timely in-
tervention with surgical aortic valve replacement or 
transcatheter aortic valve replacement.
 ► Despite the availability of guidelines for the treat-
ment of AS studies have reported non-adherence to 
these guidelines with up to 42% of AS patients not 
being treated according to these recommendations.
What does this study add?
 ► The registry will be used to outline the current man-
agement of patients with AS and determine the ade-
quacy of treatment with and without onsite access to 
surgery and percutaneous aortic valve replacement.
 ► Information will be collated about the time course 
for the transition from asymptomatic to symptom-
atic status, diagnostic work up, treatment and the 
identification of decision-makers in tertiary versus 
primary/secondary care hospitals.
How might this impact on clinical practice?
 ► The aim of the registry is to optimize clinical care 
pathways of AS and patient′s outcome in primary, 
secondary and tertiary care hospitals.
 ► In patients with transition from asymptomatic to 
symptomatic AS, identification of predictors and po-
tential triggers for rapid progress of AS will probably 
help to provide patients with better treatment op-
tions in the future.
 o
n
 20 August 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2019-001019 on 21 July 2019. Downloaded from
 
Open Heart
2 Rudolph TK, et al. Open Heart 2019;6:e001019. doi:10.1136/openhrt-2019-001019
Figure 1 Overview of IMPULSE enhanced. The IMPULSE 
enhanced registry will recruit 800 subjects with AS diagnosed 
by echocardiography. Subjects will be divided into either 
symptomatic or asymptomatic AS. A nurse will record 
subject information into an eCRF. Subject follow-up will take 
place every 3 months. Information on the patient’s status 
after intervention and their reason for exiting the registry 
will be recorded. AS, aortic stenosis; eCRF, electronic case 
report form.
over 75 years with AS and 1.0 million patients with 
severe AS.1
AS is characterised by a narrowing of the aortic valve 
opening, restricting blood flow from the left ventricle 
to the aorta and potentially affecting pressure in the left 
atrium and the pulmonary circulation. Eventually, with 
progression of stenosis severity, patients will develop 
symptoms of angina (35% of patients), syncope (15% 
of patients) or dyspnoea and/or heart failure (50% of 
patients), which without timely surgical intervention, 
result in an average survival of 2–3 years and are associ-
ated with an increased risk of sudden death.2–4 Treatment 
options for patients with severe AS include surgical aortic 
valve replacement (SAVR) and transcatheter aortic valve 
replacement (TAVR).5–7
In 2017, the European Society for Cardiology (ESC) 
and the European Association for Cardio-Thoracic 
Surgery (EACTS) published guidelines for the manage-
ment of valvular heart disease (VHD), which recom-
mend intervention with SAVR or TAVR in patients with 
severe AS, with the exception of patients with severe 
comorbidities where intervention is unlikely to improve 
either their quality of life or their chances of survival.8 
For asymptomatic patients with severe AS, intervention 
with SAVR is recommended if the patient has left ventric-
ular ejection fraction (LVEF) <50%, is physically active, 
or have the presence of risk factors (very severe AS, rele-
vant progression, markedly increased levels of B-type 
natriuretic peptide (BNP) or severe pulmonary hyper-
tension attributed to AS) and a low individual surgical 
risk.8
Several studies have reported non-adherence to guide-
lines in clinical practice and cite discrepancies between 
treatment decisions and the current scientific recommen-
dations occurring in 23%–42% of patients with AS.9–13 
Non-adherence to guidelines involved ‘overuse’ and 
‘underuse’ of interventions for AS, as well as insufficient 
diagnostics to make an informed treatment decision.13
The precedent IMPULSE registry, which evaluated the 
current practise of sAS patients showed that there is a 
high rate of delayed intervention across Europe: almost 
20% of the patients assigned to TAVR or SAVR failed 
to receive intervention within 3 months. Furthermore, 
valve replacement was also performed in asymptomatic 
patients.14
However, there is a lack of data regarding the manage-
ment of these patients in smaller centres and practices 
which do not have the possibilities to perform TAVR/
SAVR in-house.
Thus, the aims of the IMPULSE enhanced registry are 
to determine the difference in the management and 
treatment of patients with AS in primary, secondary and 
tertiary care hospitals. Furthermore, the registry will 
collect data on whether the presence of symptoms of AS 
affects the manner in which a patient is monitored and 
treated and, finally, it will determine the time course for 
the development of symptomatic AS.
RegistRy Design
IMPULSE enhanced is a multicentre, multinational, 
observational, prospective registry designed to delineate 
the case load of patients with AS, outline the manage-
ment of these patients and determine the appropriate-
ness of treatments in participating centres with and 
without onsite access to surgery and percutaneous treat-
ment (Hub: tertiary care centre; Satellite: primary or 
secondary care centre) (figure 1). The registry aims to 
enrol at least 800 patients consecutively over a 9-month 
recruitment phase, at four hubs (two hubs in Germany 
and one hub each in France and the UK) with at least 
two satellite centres per hub. The registry is established 
in accordance with the Declaration of Helsinki (1964), 
and prior ethical agreements have been obtained from 
the appropriate ethics committee at each site. Prior to 
enrolment, patients are required to provide informed 
consent and data are collected by a co-ordinating nurse 
in the form of electronic case report forms (eCRFs).
Participating sites
Patient recruitment will take place at the following hubs 
(tertiary care centres)—Kiel and Cologne (Germany), 
Paris (France) and Birmingham (UK). Each hub centre 
will select at least two satellite centres (referred to as 
secondary care centres) within a 30-mile/50-kilometre 
distance that has no onsite access to AS interventions. 
These sites are usually defined by the presence of a 
office-based cardiologist; there were no general practi-
tioners involved into the study as a secondary care centre. 
At each site, three different groups of personnel will be 
involved—physicians referring patients for echocardiog-
raphy, echocardiography technicians/physicians and a 
nurse for data acquisition.
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Patient selection
To be included in the registry, patients must be aged 
18 years or older and have a new diagnosis of severe AS 
made by transthoracic echocardiography. Severe AS is 
defined as one or more of the following criteria—aortic 
valve area of <1 cm, indexed aortic valve area of <0.6 cm/
m2, maximum jet velocity of >4.0 m/s and/or mean trans-
valvular gradient of >40 mm Hg. Patients not complying 
with the inclusion criteria, those with a diagnosis of 
non-severe AS and patients with previous AVR will be 
excluded from participation.
Data collection
All patient data will be captured on an eCRF (Software 
for Trials Europe GmbH, Berlin, Germany) and signed by 
the documenting nurse. Patient anonymity will be main-
tained through the use of a patient registry identifier 
number. Automatic checks for plausibility and complete-
ness of patient records will be performed, and the data 
manager will examine all data sets for irregularities. Any 
amends to the eCRFs will be documented. All data sets 
will be submitted for biostatistical analysis.
In addition to recording inclusion criteria, patient-re-
lated variables (patient consent, age, gender, weight, 
in-patient/out-patient status), physician-related variables 
(whether the patient was referred by a cardiologist/
cardiac surgeon, non-cardiologist/general practitioner 
or other specialist) and patient baseline characteris-
tics will be recorded. These include echocardiography 
data at baseline, medical history/symptoms at baseline 
(including details of aortic valve-related symptoms), 
comorbidities and a risk assessment based on the Euro-
pean System for Cardiac Operative Risk Evaluation I 
(EuroSCORE I, mandatory) and the EuroSCORE II 
and/or the Society of Thoracic Surgeons (STS) Score 
(optional). Frailty will be assessed at baseline and classi-
fied as none (definition: able to walk 5 m in under 6 s plus 
independent Activities of Daily Living (ADL, wash dress 
feed; toilet)), mild (definition: unable to walk 5 m under 
6 s or fails to perform one ADL) or severe (definition: 
unable to perform 2 or more ADL). There is no validation 
of the primary diagnosis of severe AS by an independent 
qualified person as we felt that the heart team preparing 
a potential intervention would in any case reconfirm and 
thus validate the diagnosis.
The main follow-up will be performed for all patients 
at 3, 6, 9 and 12 months by the documenting nurse 
contacting the referring physician (primary contact for 
the patient). Contact will be made by either telephone, 
email/fax or letter. For patients who had symptomatic AS 
at baseline, information on the treatment they received, 
who made the decision to treat and where the patient 
was treated at which date (tertiary vs primary/secondary 
care centre) will be recorded. The lead time will be deter-
mined by substracting the date of the final intervention 
(SAVR or TAVR) from the baseline visit where the new 
diagnosis of severe aortic stenosis is made. For patients 
with asymptomatic AS at baseline, information on the 
patient’s status (alive or dead, and if the latter the cause of 
death), which tests were performed after the initial echo-
cardiogram, adverse events since previous visit, details of 
interventions performed and their rationale, who made 
the decision to perform treatment and where the patient 
was treated will be recorded. If patients with asymptom-
atic AS at baseline received no intervention, then infor-
mation about patient symptoms at follow-up and further 
echocardiograms will be recorded. The eCRF will also 
record information on the patient’s status after invention 
and the reason for the patient exiting the registry.
exploratory objectives
The overall objective of the registry is to compare the 
caseload management and outcome of patients with AS in 
tertiary versus primary/secondary care hospitals and the 
appropriateness of patient management and follow-up. 
The registry is also designed to determine whether 
patient presentation (patients displaying asymptomatic 
or symptomatic AS) affects their treatment and manage-
ment. The primary objective of the registry is to deter-
mine the difference in patient treatment and manage-
ment in tertiary versus primary/secondary care hospi-
tals including the diagnostic steps, treatment decisions 
and identification of decision makers in the primary/
secondary versus tertiary care settings.
statistical analyses
The registry aims to enrol approximately 600 patients 
at the hubs (tertiary care hospitals) and 200 patients 
at the satellite centres (secondary care centres) during 
the observational period, which will enable exploration 
of the data set with enough power to determine preva-
lence rates with a narrow CI and to observe transitions 
from asymptomatic to symptomatic AS in sufficient cases 
to draw solid conclusions. Based on previous experience 
with the topic, we estimate that 22% (95%CI 3.31 for 600 
patients) of patients at the hubs will not undergo valve 
replacement despite being diagnosed with severe symp-
tomatic AS. If patients are asymptomatic but have severe 
AS, the rate is 55.6% (95%CI 3.98 for 600 patients). As 
physicians in the hub have every treatment option avail-
able, we assume that the rate of patients not undergoing 
valve replacement is higher in primary/secondary care 
facilities where other ‘watch and wait’ aspects may influ-
ence decisions. If we assume that the rates for conserva-
tive treatment are 40% (95%CI 6.79 for 200 patients) for 
symptomatic and 75% (95%CI 6.00) for asymptomatic 
patients at the primary/secondary care facility, we would 
be able to confirm the difference as CIs will not overlap.
The intention-to-treat analysis will include all patients 
enrolled in the registry. Descriptive data summaries will 
be used to present and summarise the collected evalu-
ation data. Frequency distributions will be provided for 
categorical variables (eg, gender). For numeric variables 
(eg, patient age) the minimum, maximum, mean, median 
and SD will be calculated by Kaplan-Meier analyses to 
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determine survival outcomes. Where applicable, univar-
iate and multivariate analyses will be performed.
DisCussion
In the present international, multicentre, prospective, 
observational registry, the aim is to gather data on the 
impact of managing and/or treating patients with severe 
AS at primary, secondary and tertiary care centres in 
Europe. The level of information captured on the eCRF 
forms will also allow determination of the appropriate-
ness of treatments, the time course for the development 
of symptomatic AS and the identification of key deci-
sion-makers within the medical profession for the treat-
ment of AS. In addition, the registry data may also help 
to identifying areas for care improvement.
Current practice
Treatment guidelines, which summarise and evaluate avail-
able scientific evidence, are designed to assist healthcare 
physicians in selecting the optimal management strategies 
for an individual patient with a given condition. In 2012, 
the ESC/EACTS developed guidelines for the treatment 
and management of patients with VHD.15 In 2017, these 
guidelines were updated with new evidence on percuta-
neous interventional techniques and on risk stratifica-
tion with regard to the timing of intervention of VHD.8 
The task of developing these guidelines also includes the 
development of various tools, including condensed pocket 
versions, summary slides, booklets with essential messages 
and an electronic version for digital applications, to ensure 
that they are as widely adopted as possible. Despite these 
tools, however, early studies suggest that the implementa-
tion of and adherence to guidelines for the treatment of 
patients with AS still needs to be addressed. One study in 
patients aged 75 years or older suggested that surgery was 
denied in a third of patients with severe symptomatic AS, 
with the main unduly reasons for this decision being their 
advancing age and LV dysfunction rather than associated 
comorbidities as detailed in the guidelines.10 Another 
retrospective study, which also sought to understand if 
there were specific patient characteristics that impacted 
on the decision-making to treat symptomatic AS, revealed 
that 73 (69%) patients did not undergo AVR with the most 
common reason being cited that the patient’s symptoms 
were not thought to be related to AS. With an average 
follow-up of 15 months, 15 (14%) of these 73 patients 
had died. The study concluded that physicians commonly 
under-recognise symptoms of AS and overestimated the 
operative risk, resulting in too few patients receiving a life-
saving intervention.12 Intervention is also recommended 
in selected patients with asymptomatic AS. Of the 5001 
patients assessed in this study, 84 patients had severe asymp-
tomatic AS, but stress testing was performed in only 6 (4%) 
patients and a decision to operate was made in 45 (54%) 
patients. The indications for surgery were in accordance 
with the American College of Cardiology/American Heart 
Association guidelines in 57 (68%) patients for AS, but the 
decision to operate was frequently based on class IIb recom-
mendations. The study concluded that intervention was 
‘overused’ in 18 (21%) patients with AS and ‘underused’ in 
9 (11%) patients with AS.13
The IMPULSE registry, which enrolled 2171 patients 
of hospitals with all treatment options (SAVR, TAVR, 
balloon aortic valvuloplasty (BAV)), showed a high rate 
of decision for conservative treatment in about a third 
of patients (31.1%). In 69% (n=1379) of the patients a 
valve replacement was chosen (66% TAVR vs 34% SAVR). 
Of these patients, the intervention was not performed 
within 3 months in 18.4% (n=254). By contrast, an inter-
vention was performed in patients with asymptomatic AS 
in the absence of class I/IIa indication in a considerable 
number of cases (23% TAVR vs 17% SAVR). There was 
no clear decision pattern for this except a higher rate of 
reduced LVEF.14
To the best of our knowledge, there is no data on the 
impact of hospital type and adherence to treatment 
guidelines for patients with AS. For other cardiology 
conditions, a study in the USA comparing hospital 
treatment of patients with acute myocardial infarction 
showed that there was no significant difference between 
process measures and patient outcomes by hospital 
type or the availability of interventional capabilities.16 
There is some evidence to show that the setting in which 
a cardiology patient is diagnosed may impact on their 
treatment and management, with patients being diag-
nosed in hospitals versus primary care being referred for 
more investigative procedures but this may be because 
patients who present to hospitals tend to have more 
symptoms and/or a higher disease burden.17 Again, 
to our knowledge, there is no comparable data on the 
medical location impacting the diagnosis or treatment 
of patients with AS.
improved intervention
Factors which are associated with an increased risk of 
developing severe AS include patients who develop a rapid 
increase in aortic jet velocity and associated coronary artery 
disease.18 To help improve the treatment of severe AS, a 
better understanding of potential triggers in patients with 
asymptomatic AS that result in the rapid development 
of symptoms and multivariate predictors for developing 
severe disease are needed. The steps to diagnose AS are 
fairly well documented and include a physical examination 
and a transthoracic echocardiogram (including the assess-
ment of various echocardiographic features to determine 
disease severity).19 Diagnosis, however, can be hampered 
by the presence of cardiac comorbidities such as coronary 
artery disease and particularly heart failure as well as lung 
disease.2–4 20 Assimilation of detailed data on the triggers 
of rapid disease progression, disease-associated risk factors 
and diagnostic procedures could be used to develop clin-
ical care pathways for the treatment of patients with asymp-
tomatic and symptomatic AS.
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Pending issues
The IMPULSE enhanced registry was set up to establish 
the adherence to treatment guidelines and the identifica-
tion, treatment and management of patients with AS in the 
primary, secondary and tertiary care settings. There are, 
however, various factors that the registry does not take into 
consideration. In some countries, such as the UK, a patient 
cannot select the hospital in which they would like to be 
treated. The IMPULSE enhanced registry records which 
physicians (eg, general practitioners and cardiologists) 
have referred patients to the hubs and satellite centres 
involved in the registry but does not consider country-spe-
cific nuances in hospital selection or that patients/patient 
families could have requested treatment at specific care 
institutions. It is possible that, for example, patients with 
more complex needs may choose larger hospitals due to 
the range of available treatments or the type of patient care 
offered. Similarly, hospital selection could be the result of 
its location/accessibility to the patient and their family.
The registry is currently set up to review patient care once 
at a medical institution but the findings of this registry may 
also help to provide guidance on treatment location based 
on the availability of treatment options/procedures and 
adherence to guideline recommendations. Secondary care 
centres, by their very nature, do not have access to surgical 
and percutaneous aortic valve interventions. It may be, for 
example, that patients with asymptomatic or mildly symp-
tomatic AS could initially be seen at secondary care centres, 
while those presenting with severe symptomatic AS should 
be treated with more urgency and referred to tertiary care 
centres. This may also skew the data to suggest that, on 
paper, tertiary care centres have better adherence to treat-
ment guidelines. Once all the registry data are available 
and analysed, it will be interesting to see if disease severity 
influences the final destination for patient care and, as a 
result, whether separate guideline recommendations need 
to be developed to accommodate this.
ConClusions
The aim of the IMPULSE enhanced registry is to provide 
high-quality data regarding the implementation and adher-
ence to guidelines for the treatment and management of 
patients with AS in the primary, secondary and tertiary 
care settings. Information gained from this registry can be 
used to develop a clinical care pathway that can be applied 
across all patient services, irrespective of care facilities, to 
ensure that patients with AS receive optimal treatment 
and management in a timely manner. Overall, the hope is 
that the development of clinical care pathways that can be 
readily adopted by patient services will result in a reduction 
in morbidity and mortality associated with AS.
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